Revolution Medicines (RVMD) Stock Overview
A clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RVMD Community Fair Values
Create NarrativeSee what 24 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Revolution Medicines, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$189.23 |
| 52 Week High | US$193.83 |
| 52 Week Low | US$34.00 |
| Beta | 1.38 |
| 1 Month Change | 3.93% |
| 3 Month Change | 43.72% |
| 1 Year Change | 399.22% |
| 3 Year Change | 636.02% |
| 5 Year Change | 560.72% |
| Change since IPO | 554.78% |
Recent News & Updates
RVMD: FDA Review And RAS Portfolio Progress Point To Balanced Future
Analysts have lifted the updated fair value estimate for Revolution Medicines from about $133.70 to roughly $204.38, citing higher assumed revenue growth, stronger profit margins, and more moderate future P/E expectations. These changes follow a series of price target increases tied to daraxonrasib data, regulatory progress, and combination therapy readouts.
RVMD: Pancreatic Cancer Survival Breakthrough Will Drive Repricing Of Future Prospects
Revolution Medicines' analyst price targets have shifted higher, with several firms moving into a $182 to $235 range. Analysts point to updated RASolute-302 data, strengthened expectations for daraxonrasib and zoldonrasib across pancreatic ductal adenocarcinoma and other RAS-mutant cancers, and more constructive views on long term revenue potential.Recent updates
RVMD: FDA Review And RAS Portfolio Progress Point To Balanced Future
Analysts have lifted the updated fair value estimate for Revolution Medicines from about $133.70 to roughly $204.38, citing higher assumed revenue growth, stronger profit margins, and more moderate future P/E expectations. These changes follow a series of price target increases tied to daraxonrasib data, regulatory progress, and combination therapy readouts.RVMD: Pancreatic Cancer Survival Breakthrough Will Drive Repricing Of Future Prospects
Revolution Medicines' analyst price targets have shifted higher, with several firms moving into a $182 to $235 range. Analysts point to updated RASolute-302 data, strengthened expectations for daraxonrasib and zoldonrasib across pancreatic ductal adenocarcinoma and other RAS-mutant cancers, and more constructive views on long term revenue potential.
RVMD: Survival Breakthrough In Pancreatic Cancer Will Likely Not Justify Current Pricing
Analysts lifted their average price target on Revolution Medicines to $151, up from $92.22, citing stronger Phase 3 daraxonrasib data in pancreatic ductal adenocarcinoma and growing confidence in the drug's role across RAS-mutant cancers as key drivers of the shift. Analyst Commentary Recent research coverage around Revolution Medicines centers on daraxonrasib, the RASolute 302 data presented at ASCO, and combination trials in pancreatic ductal adenocarcinoma.Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Summary Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD’s $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib’s Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity. RVMD trades at extreme valuation multiples, reflecting high expectations for commercial success and platform expansion into broader RAS-driven cancers. Read the full article on Seeking AlphaLate Stage RAS Oncology Pipeline Will Reshape Long Term Cancer Treatment Options
Catalysts About Revolution Medicines Revolution Medicines focuses on targeted therapies for cancers driven by RAS mutations. What are the underlying business or industry changes driving this perspective?Late Stage RAS Oncology Pipeline Will Face Heavy Costs Yet Eventually Support Stable Long Term Outlook
Catalysts About Revolution Medicines Revolution Medicines focuses on targeted therapies for cancers driven by RAS mutations, with a pipeline of RAS(ON) inhibitors across pancreatic, lung and colorectal indications. What are the underlying business or industry changes driving this perspective?RAS Oncology Catalysts Will Drive A Transformational Long Term Opportunity
Catalysts About Revolution Medicines Revolution Medicines focuses on targeted therapies for cancers driven by RAS mutations, with a broad portfolio of RAS(ON) inhibitors across multiple tumor types. What are the underlying business or industry changes driving this perspective?Revolution Medicines: Overpriced RAS-Addicted Cancers Maven
Summary Revolution Medicines is a clinical-stage pharma company with a market cap of ~6 billion. It has ample liquidity to support its current business plan into 2027. Its pipeline directed entirely towards RAS-addicted cancers includes two phase 3 trials that are still enrolling patients. Investment thesis: Revolution's hefty market cap belies its speculative prospects, particularly in the current market environment. Read the full article on Seeking AlphaShareholder Returns
| RVMD | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.6% | -1.3% | -1.0% |
| 1Y | 399.2% | 29.0% | 14.7% |
Return vs Industry: RVMD exceeded the US Biotechs industry which returned 29% over the past year.
Return vs Market: RVMD exceeded the US Market which returned 14.7% over the past year.
Price Volatility
| RVMD volatility | |
|---|---|
| RVMD Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RVMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RVMD's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 883 | Mark Goldsmith | www.revmed.com |
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C).
Revolution Medicines, Inc. Fundamentals Summary
| RVMD fundamental statistics | |
|---|---|
| Market cap | US$40.23b |
| Earnings (TTM) | -US$1.37b |
| Revenue (TTM) | n/a |
Is RVMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RVMD income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$1.13b |
| Gross Profit | -US$1.13b |
| Other Expenses | US$246.15m |
| Earnings | -US$1.37b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.7% |
How did RVMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/26 04:50 |
| End of Day Share Price | 2026/07/24 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Revolution Medicines, Inc. is covered by 34 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Walch | Bernstein |
| Alec Stranahan | BofA Global Research |
| Cory Kasimov | Evercore ISI |